By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro ...

AstraZeneca has partnered with AI biotech insitro to identify drug targets and develop potential treatments for MASH, a ...

AstraZeneca will use insitro’s AI platform to identify potential drug targets for MASH and cardiomyopathies, drawing on its ...

AstraZeneca said it is teaming up with startup Insitro to deploy artificial intelligence to explore new treatments for cardiometabolic diseases in a deal valued at as much as $1.5 billion.

AstraZeneca (AZN) on Thursday announced an AI-driven drug discovery and licensing deal worth up to $1.5B with ...

TDB will provide Rs 86 crore to Peptris Technologies for a Rs 172-crore project to advance four AI-discovered experimental ...

Detailed analyses of ligand choice, linkage vector and linker length enabled the development of bitopic inhibitors of ABL1 and EGFR kinases, including an ABL1 inhibitor with enhanced activity against ...

Pharmaceutical & Biotech Stock Introductory Series, Part 2, Episode 9 / 12 total]IntroductionSchrödinger (SDGR) is a company ...

AstraZeneca (AZN) signed a drug-discovery deal with AI biotech insitro on Thursday, October 15, aimed at MASH, a serious liver disease, and cardiomyopathies, a group of heart-muscle diseases. The ...

Holbrook most recently led cardiovascular, renal and hepatic disease and in vitro discovery platforms at Novo Nordisk; she ...

Funding from the Gates Foundation supports development of open-access AI models, workflows and datasets to help researchers identify new tuberculosis (TB) targets for faster and more cost-effective ...

The European Innovation Council (EIC) has decided to grant significant funding to the Greek research project “Mini Proteins ...